Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

Wilfred Truin, Rudi M.H. Roumen, Sabine Siesling, Koen K. van de Vijver, Vivianne C.G. Tjan-Heijnen, Adri C. Voogd

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
58 Downloads (Pure)

Abstract

Background
Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.

Methods
We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10–69, 70–89, and ≥90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.

Results
In total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50–69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.

Conclusion
Patients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.
Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalBreast cancer research and treatment
Volume164
Issue number1
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Lobular Carcinoma
Ductal Carcinoma
Progesterone Receptors
Estrogen Receptors
Estrogens
Progesterone
Hormones
Neoplasms
Netherlands
Registries
Age Groups

Cite this

Truin, Wilfred ; Roumen, Rudi M.H. ; Siesling, Sabine ; van de Vijver, Koen K. ; Tjan-Heijnen, Vivianne C.G. ; Voogd, Adri C. / Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. In: Breast cancer research and treatment. 2017 ; Vol. 164, No. 1. pp. 133-138.
@article{d62430555716499b8cf104ecf922c90f,
title = "Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors",
abstract = "BackgroundDifferences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.MethodsWe included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10–69, 70–89, and ≥90{\%}. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.ResultsIn total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17{\%} were ILC and 83{\%} IDC. In patients with IDC, 86{\%} of the tumors showed an ER expression level of 90{\%} or more, compared to 84{\%} in those with ILC. In both IDC and ILC a PR expression level of 90{\%} or more was observed in 54{\%} of the tumors. In postmenopausal patients aged 50–69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.ConclusionPatients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.",
author = "Wilfred Truin and Roumen, {Rudi M.H.} and Sabine Siesling and {van de Vijver}, {Koen K.} and Tjan-Heijnen, {Vivianne C.G.} and Voogd, {Adri C.}",
year = "2017",
month = "7",
doi = "10.1007/s10549-017-4220-x",
language = "English",
volume = "164",
pages = "133--138",
journal = "Breast cancer research and treatment",
issn = "0167-6806",
publisher = "Springer",
number = "1",

}

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. / Truin, Wilfred; Roumen, Rudi M.H.; Siesling, Sabine ; van de Vijver, Koen K.; Tjan-Heijnen, Vivianne C.G.; Voogd, Adri C.

In: Breast cancer research and treatment, Vol. 164, No. 1, 07.2017, p. 133-138.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

AU - Truin, Wilfred

AU - Roumen, Rudi M.H.

AU - Siesling, Sabine

AU - van de Vijver, Koen K.

AU - Tjan-Heijnen, Vivianne C.G.

AU - Voogd, Adri C.

PY - 2017/7

Y1 - 2017/7

N2 - BackgroundDifferences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.MethodsWe included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10–69, 70–89, and ≥90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.ResultsIn total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50–69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.ConclusionPatients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.

AB - BackgroundDifferences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.MethodsWe included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10–69, 70–89, and ≥90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.ResultsIn total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50–69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.ConclusionPatients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.

U2 - 10.1007/s10549-017-4220-x

DO - 10.1007/s10549-017-4220-x

M3 - Article

VL - 164

SP - 133

EP - 138

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

SN - 0167-6806

IS - 1

ER -